Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia - Stand Up To Cancer

Blog

Posted October 11, 2019

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.